Scientists provide proof of concept for potential new class of cancer drugs

A small-molecule inhibitor of the Notch pathway has been discovered by scientists, paving the way for a potential new class of personalized cancer medicines. Aberrant activity in the Notch pathway contributes to the initiation and maintenance of cancer stem cells.